QualityDipStocks / Health Care · Medical Specialities
Oscar Health OSCR
Outside our quality screen, so we don’t track its dips. It’s 10% below its 52-week high.
Outside our quality screen. No fair value estimate for now: the model’s result is too extreme to stand behind.
Worth knowing
- Net cash = 79% of its market cap
- ROE 34% and more cash than debt
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- $31.18price −1%
- Off 52-wk high
- −10%
- Risk vs market
- Above marketbeta 1.28
5 bullish · 4 bearish See why
Repriced or dip?
Near its high
The price is 10% below its 52-week high (Oct 14), but the business held up: net cash (cash minus debt) 0.0% of market cap since the high, shares outstanding unchanged, operating margin 0.0 pts.
Some numbers held up (net cash (cash minus debt) 0.0% of market cap since the high, shares outstanding unchanged, operating margin 0.0 pts), others slipped. The price is 10% below its 52-week high.
The price is 10% below its 52-week high, and the business changed too.
Within 10% of its 52-week high, so there is no dip to judge yet.
Data-based read, not advice.
Priced in
How much growth the market assumed at the 52-week high, the low and today (a reverse DCF).
At the high ($34.32, Oct 14) the price assumed about −29%/yr free-cash-flow growth. The last 3 years delivered 44%/yr (free cash flow).
Dashed line: what the last 3 years delivered, 44%/yr (free cash flow)
| High | Now | |
|---|---|---|
| Price | $34.32Oct 14 | $31.00 |
| Implied growth | −29% | below −30% |
| P/E | 20.8× | 18.8× |
| P/FCF | 2.6× | 2.4× |
| EV/Sales | 0.2× | 0.1× |
What this means: the higher the implied growth, the more the price already counts on. If today's number sits well below what the business has delivered, the market expects less than its track record.
How it’s computed
Reverse DCF: the same 10-year free-cash-flow model as our fair value estimate (9.5% discount rate, growth for years 1–5 fading to 3% by year 10, 3% after), solved for the growth that makes it equal the market value at each price. For the high and the low we use only the filings that were public on that day, so nothing from a later report leaks back. Market value = that close × diluted shares. P/E = market value / 12-month net income; Price / FCF = market value / 12-month free cash flow; EV / Sales = (market value + debt − cash) / 12-month revenue. Hidden when the share count moved over 20% (split, merger), free cash flow is negative, or the company reports in another currency.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
Estimate unreliable for OSCR: the model gives 1207% above the price, more than we can stand behind (usually peak-cycle cash flow, heavy debt, or cash flows that include customer or loan balances). We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much OSCR moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings more than the market, and its own price swings are 5.2× the S&P 500’s.
- Beta vs S&P 500
- 1.28
- Volatility
- 67% vs 13% SPY
- Correlation SPY
- 0.24
- Correlation QQQ
- 0.17
How it ranks
Where OSCR stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Top quarter on 2 of 4 measures
- Free cash flow yield42% · free cash flow vs market capTop 1%of 1,391
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 1,836
- Revenue growth, last 12 months+43% · vs the 12 months beforeTop 9%of 1,814
- Operating margin4.1% · of sales kept as operating profitLowest 23%of 1,288
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $31.18 · FCF value $55.70
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
ValuationFree-cash-flow yield of 42.4% (price / FCF 2.4×): $4.4B of free cash in the last 12 months.
GrowthSales grew 43% to $15.3B over the last 12 months vs the 12 months before (SEC filings).
GrowthSales compounded 43% a year from FY2022 to FY2025.
Balance sheetNet cash of $8.1B: cash and short-term investments exceed debt (Jun 30, 2026).
Cash returnsFree cash flow grew 265% over the last 12 months vs the 12 months before.
Top bearish points 4 of 5
Cash returnsShare count up 30.5% in a year: existing holders are being diluted.
ProfitabilityReturn on equity fell 12 points in two fiscal years, to -45% in FY2025.
ProfitabilityOperating margin of 4.1%, below the 9.3% median for the 175 Health Care companies we cover.
RiskReports earnings Nov 5 (consensus EPS ($0.11)): results can move the price sharply and reset Market Value.
All fundamentals
P/E 18.8 · FCF yield 42.4% · ROE 34%
Valuation
- P/E
- 18.8×Health Care median 29.0×
- Price / FCF
- 2.4×
- FCF yield
- 42.4%
- EV / EBITDA
- 3.4×
- Price / sales
- 0.67×
- Price / book
- 5.04×
- Market cap
- $10.3Bprice × diluted shares
- Enterprise value
- $2.2B
Growth
- Revenue, 12 months
- $15.3B
- Sales growth, 12 months
- +42.8%vs the 12 months before
- Sales growth, 3 yrs
- +43.5%/yrfrom FY2022
- Diluted EPS, 12 months
- $1.30
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- $551M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- 4.1%
- Net margin
- 3.6%
- FCF margin
- 28.6%
- Return on equity
- 34%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $8.6B
- Total debt
- $432M
- Net cash
- $8.1B
- Debt / equity
- 0.21×
- Interest coverage
- 39.7×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $4.4B
- FCF growth, 12 months
- +265%
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +30.5%diluted shares vs a year ago
- Stock-based comp
- $75M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Oscar Health’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $0.7B · Sales +70%
- Free cash flow, 12 months$0.7B
- Free-cash-flow yield42.4%
- Free-cash-flow margin4%
- Gross margin20%
- Operating margin8%
- Return on equity34%
- Sales growth (latest quarter vs year-ago quarter)+70%
- Net debt / EBITDA−12.3×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $31.00
- 52-wk lowlowest close, 1 year$10.85−65.0%
- PriceMon Nov 2 close$31.00you are here
- Market Valueavg paid since Aug 6$31.18+0.6%
- 52-wk highhighest close, 1 year$34.32+10.7%
Momentum & 52-week range
RSI 46 · 5 days −0.3%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 5
- DateThu Nov 5, before the open
- Consensus EPS($0.11)
- Year-ago EPS($0.53)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
OSCR is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Oscar Health in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Medical Specialities
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.